谷本光音

Severe Case of Peripheral Leukocytosis Initially Diagnosed as Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, but Possibly Prefibrotic Primary Myelofibrosis

JaLCDOI	10.18926/AMO/53025
フルテキストURL	68_6_363.pdf
著者	Ota, Seisuke\| Hiramatsu, Yasushi\| Kondo, Eisei\| Kasahara, Akinori\| Takada, Saimon\| Umena, Sachio\| Noguchi, Toshio\| Tanimoto, Mitsune\| Matsumura, Tadashi\|
抄録	Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×10⁵/μL. Gastroenteroscopy revealed an acute gastric and duodenal mucosal lesion that was treated successfully via endoscopic hemoclipping. Bone marrow aspiration revealed marked megakaryocyte proliferation with atypia of naked nuclei and marrow hypercellularity (90% cellularity). A fluorescence in situ hybridization test could not detect the BCR-ABL fusion gene. Bone marrow aspiration later revealed further abnormalities of megakaryocytes. The patient died from cerebral bleeding. The present case fulfilled 2 of the 3 major criteria of primary myelofibrosis according to the World Health Organization 2008 classification:namely, megakaryocytic hyperplasia with hypercellular marrow and granulocytic hyperplasia. However, the megakaryocytic abnormality was not strictly compatible with the criteria. Instead, we considered prefibrotic primary myelofibrosis as a possibility, although myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) was technically the correct diagnosis. The present case shows that MPN diagnosis remains difficult and suggests that other cases of peripheral leukocytosis with diagnosed MDS/MPN-U might include similar findings.
キーワード	prefibrotic primary myelofibrosis leukocytosis anemia acute gastric mucosal lesion multiple cerebral hemorrhages
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2014-12
巻	68巻
号	6号
出版者	Okayama University Medical School
開始ページ	363
終了ページ	368
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	25519030
Web of Science KeyUT	000346882200006

Pilot Analysis of Asbestos-induced Diffuse Pleural Thickening with Respiratory Compromise

JaLCDOI	10.18926/AMO/53671
フルテキストURL	69_5_261.pdf
著者	Nojima, Daisuke\| Fujimoto, Nobukazu\| Kato, Katsuya\| Fuchimoto, Yasuko\| Kiura, Katsuyuki\| Kishimoto, Takumi\| Tanimoto, Mitsune\|
抄録	We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
キーワード	asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2015-10
巻	69巻
号	5号
出版者	Okayama University Medical School
開始ページ	261
終了ページ	266
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	26490022
Web of Science KeyUT	000365519600001

Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation

JaLCDOI	10.18926/AMO/54499
フルテキストURL	70_4_243.pdf
著者	Osawa, Masahiro\| Ohashi, Kadoaki\| Kubo, Toshio\| Ichihara, Eiki\| Takata, Saburo\| Takigawa, Nagio\| Takata , Minoru\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
抄録	Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
キーワード	vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2016-08
巻	70巻
号	4号
出版者	Okayama University Medical School
開始ページ	243
終了ページ	253
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27549668
Web of Science KeyUT	000384748600003

Heerfordt’s Syndrome Associated with a High Fever and Elevation of TNF-α

JaLCDOI	10.18926/AMO/54503
フルテキストURL	70_4_273.pdf
著者	Makimoto, Go\| Miyahara, Nobuaki\| Yoshikawa, Mao\| Taniguchi, Akihiko\| Kanehiro, Arihiko\| Tanimoto, Mitsune\| Kiura, Katsuyuki\|
抄録	Heerfordtʼs syndrome is a rare manifestation of sarcoidosis and is defined as a combination of facial palsy, parotid swelling, and uveitis, associated with a low-grade fever. We report a case of Heerfordtʼs syndrome presenting with a high fever and increased serum tumor necrosis factor alpha (TNF-α) levels. The patient had facial palsy, parotid swelling, uveitis, and swelling of the right supraclavicular and hilar lymph nodes. Corticosteroid therapy was initiated, and her symptoms soon resolved completely, in tandem with a decrease in TNF-α serum levels.
キーワード	Heerfordtʼs syndrome sarcoidosis TNF-α
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2016-08
巻	70巻
号	4号
出版者	Okayama University Medical School
開始ページ	273
終了ページ	277
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27549672
Web of Science KeyUT	000384748600007

An Open-labeled, Multicenter Phase II Study of Tamibarotene in Patients with Steroid-refractory Chronic Graft-versus-Host Disease

JaLCDOI	10.18926/AMO/54603
フルテキストURL	70_5_409.pdf
著者	Maeda, Yoshinobu\| Nishimori, Hisakazu\| Inamoto, Yoshihiro\| Nakamae, Hirohisa\| Sawa, Masashi\| Mori, Yasuo\| Ohashi, Kazuteru\| Fujiwara, Shin-ichiro\| Tanimoto, Mitsune\|
抄録	Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
キーワード	Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type	Clinical Study Protocols
出版物タイトル	Acta Medica Okayama
発行日	2016-10
巻	70巻
号	5号
出版者	Okayama University Medical School
開始ページ	409
終了ページ	412
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27777437
Web of Science KeyUT	000388098700014

Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease

JaLCDOI	10.18926/AMO/54608
フルテキストURL	70_5_429.pdf
著者	Asano, Takeru\| Matsuoka, Ken-ichi\| Iyama, Satoshi\| Ohashi, Kazuteru\| Inamoto, Yoshihiro\| Ohwada, Chikako\| Murata, Makoto\| Satake, Atsushi\| Yoshida, Chikamasa\| Nakase, Koichi\| Mori, Yasuo\| Tanimoto, Mitsune\|
抄録	Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.
キーワード	chronic GVHD allogeneic HSCT steroid refractory IL-2
Amo Type	Clinical Study Protocols
出版物タイトル	Acta Medica Okayama
発行日	2016-10
巻	70巻
号	5号
出版者	Okayama University Medical School
開始ページ	429
終了ページ	433
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	27777442
Web of Science KeyUT	000388098700019

集学的治療により長期生存が得られた食道神経内分泌癌の2 例

著者	後藤田達洋\| 川野誠司\| 河野吉泰\| 三浦公\| 神崎洋光\| 岩室雅也\| 河原祥朗\| 田中健大\| 吉野正\| 白川靖博\| 田端雅弘\| 谷本光音\| 岡田裕之\|
発行日	2016-12-01
出版物タイトル	岡山医学会雑誌
巻	128巻
号	3号
資料タイプ	学術雑誌論文

第7 回日本血液学会（IJH）国際シンポジウム報告

著者	谷本光音\|
発行日	2016-12-01
出版物タイトル	岡山医学会雑誌
巻	128巻
号	3号
資料タイプ	一般雑誌記事

Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease

JaLCDOI	10.18926/AMO/55446
フルテキストURL	71_5_453.pdf
著者	Taniguchi, Akihiko\| Miyahara, Nobuaki\| Oda, Naohiro\| Morichika, Daisuke\| Ichihara, Eiki\| Oze, Isao\| Tanimoto, Yasushi\| Ichikawa, Hirohisa\| Fujii, Utako\| Tanimoto, Mitsune\| Kanehiro, Arihiko\| Kiura, Katsuyuki\|
抄録	Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
キーワード	chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type	Clinical Study Protocol
出版物タイトル	Acta Medica Okayama
発行日	2017-10
巻	71巻
号	5号
出版者	Okayama University Medical School
開始ページ	453
終了ページ	457
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2017 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	29042706

Effect of a Cyclooxygenase-2 Inhibitor in Combination with (−)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice

JaLCDOI	10.18926/AMO/64363
フルテキストURL	77_1_65.pdf
著者	Sato, Ken\| Takigawa, Nagio\| Kubo, Toshio\| Katayama, Hideki\| Kishino, Daizo\| Okada, Toshiaki\| Hisamoto, Akiko\| Mimoto, Junko\| Ochi, Nobuaki\| Yoshino, Tadashi\| Ueoka, Hiroshi\| Tanimoto, Mitsune\| Maeda, Yoshionobu\| Kiura, Katsuyuki\|
抄録	We investigated the effects of celecoxib combined with (−)-epigallocatechin-3-gallate (EGCG) or polyphenon E in a cisplatin-induced lung tumorigenesis model. Four-week-old female A/J mice were divided into seven groups: (i) Control, (ii) 150 mg/kg celecoxib (150Cel), (iii) 1,500 mg/kg celecoxib (1500Cel), (iv) EGCG+150 mg/kg celecoxib (EGCG+150Cel), (v) EGCG+1,500 mg/kg celecoxib (EGCG+1500Cel), (vi) polyphenon E+150 mg/kg celecoxib (PolyE+150Cel), and (vii) polyphenon E+1,500 mg/kg celecoxib (PolyE+1500Cel). All mice were administered cisplatin (1.62 mg/kg of body weight, i.p.) 1×/week for 10 weeks and sacrificed at week 30; the numbers of tumors on the lung surface were then determined. The tumor incidence and multiplicity (no. of tumors/mouse, mean±SD) were respectively 95% and 2.15±1.50 in Control, 95% and 2.10±1.29 in 150Cel, 86% and 1.67±1.20 in 1500Cel, 71% and 1.38±1.24 in EGCG+150Cel, 67% and 1.29±1.38 in EGCG+1500Cel, 80% and 1.95±1.36 in PolyE+150Cel, and 65% and 1.05±0.10 in PolyE+1500Cel. The combination of high-dose celecoxib with EGCG or polyphenon E significantly reduced multiplicity in cisplatin-induced lung tumors.
キーワード	celecoxib cisplatin EGCG lung tumor polyphenon E
Amo Type	Original Article
出版物タイトル	Acta Medica Okayama
発行日	2023-02
巻	77巻
号	1号
出版者	Okayama University Medical School
開始ページ	65
終了ページ	70
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	Copyright Ⓒ 2023 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	36849147
Web of Science KeyUT	000952992100004

HCV感染がRCHOP療法下でのDLBCLにおける肝障害と予後に与える影響

著者	遠西大輔\| 谷本光音\|
発行日	2011-08-01
出版物タイトル	岡山医学会雑誌
巻	123巻
号	2号
資料タイプ	学術雑誌論文

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401

著者	Nogami, Naoyuki\| Hotta, Katsuyuki\| Kuyama, Shoichi\| Kiura, Katsuyuki\| Takigawa, Nagio\| Chikamori, Kenichi\| Shibayama, Takuo\| Kishino, Daizo\| Hosokawa, Shinobu\| Tamaoki, Akihiko\| Harita, Shingo\| Tabata, Masahiro\| Ueoka, Hiroshi\| Shinkai, Tetsu\| Tanimoto, Mitsune\|
発行日	2011-10
出版物タイトル	Lung Cancer
巻	74巻
号	1号
資料タイプ	学術雑誌論文

新型インフルエンザウイルス（A/H1N1）感染後にARDSを来たした1例

著者	谷口暁\| 宮原信明\| 中原淳\| 高田三郎\| 佐久川亮\| 長野修\| 谷本安\| 金廣有彦\| 木浦勝行\| 氏家良人\| 谷本光音\|
発行日	2011-12-01
出版物タイトル	岡山医学会雑誌
巻	123巻
号	3号
資料タイプ	学術雑誌論文

同種抗原による移植片対白血病効果減弱のメカニズム

著者	朝倉昇司\| 橋本大吾\| 高嶋秀一郎\| 杉山暖子\| 前田嘉信\| 赤司浩一\| 谷本光音\| 豊嶋崇徳\|
発行日	2012-04-01
出版物タイトル	岡山医学会雑誌
巻	124巻
号	1号
資料タイプ	学術雑誌論文

合成レチノイドAm80はTh1とTh17を抑制することにより慢性移植片対宿主病を改善する

著者	西森久和\| 前田嘉信\| 谷本光音\|
発行日	2012-12-03
出版物タイトル	岡山医学会雑誌
巻	124巻
号	3号
資料タイプ	学術雑誌論文

EGFRチロシンキナーゼ阻害薬耐性肺癌細胞に対するmicroRNA-7発現プラスミドのリポソームを用いた導入による克服の検討

著者	頼冠名\| 瀧川奈義夫\| 伊藤佐智夫\| 柏原宏美\| 市原英基\| 保田立二\| 清水憲二\| 谷本光音\| 木浦勝行\|
発行日	2012-12-03
出版物タイトル	岡山医学会雑誌
巻	124巻
号	3号
資料タイプ	学術雑誌論文

Antimicrobial effects of the saliva substitute, Oralbalance (R), against microorganisms from oral mucosa in the hematopoietic cell transplantation period

著者	Sugiura, Yuko\| Soga, Yoshihiko\| Tanimoto, Ichiro\| Kokeguchi, Susumu\| Nishide, Sachiko\| Kono, Kotoe\| Takahashi, Kanayo\| Fujii, Nobuharu\| Ishimaru, Fumihiko\| Tanimoto, Mitsune\| Yamabe, Kokoro\| Tsutani, Soichiro\| Nishimura, Fusanori\| Takashiba, Shogo\|
発行日	2008-04
出版物タイトル	Supportive Care in Cancer
巻	16巻
号	4号
資料タイプ	学術雑誌論文

Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward

著者	Soga, Yoshihiko\| Sugiura, Yuko\| Takahashi, Kanayo\| Nishimoto, Hitomi\| Maeda, Yoshinobu\| Tanimoto, Mitsune\| Takashiba, Shogo\|
発行日	2011-02
出版物タイトル	Supportive Care in Cancer
巻	19巻
号	2号
資料タイプ	学術雑誌論文

Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device

著者	Sugiura, Yuko\| Soga, Yoshihiko\| Nishide, Sachiko\| Kono, Kotoe\| Takahashi, Kanayo\| Fujii, Nobuharu\| Ishimaru, Fumihiko\| Tanimoto, Mitsune\| Nishimura, Fusanori\| Takashiba, Shogo\|
発行日	2008-10
出版物タイトル	Supportive Care in Cancer
巻	16巻
号	10号
資料タイプ	学術雑誌論文

Preparation of Enteric-coated Capsules of Beclomethasone Dipropionate for Patients with Intestinal Graft-versus-Host Disease and a Case Study

JaLCDOI	10.18926/AMO/51868
フルテキストURL	67_5_319.pdf
著者	Murakawa, Kiminaka\| Sato, Tomoaki\| Maeda, Yoshinobu\| Kitamura, Yoshihisa\| Tanimoto, Mitsune\| Sendo, Toshiaki\|
抄録	Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.
キーワード	beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation
Amo Type	Case Report
出版物タイトル	Acta Medica Okayama
発行日	2013-10
巻	67巻
号	5号
出版者	Okayama University Medical School
開始ページ	319
終了ページ	324
ISSN	0386-300X
NCID	AA00508441
資料タイプ	学術雑誌論文
言語	英語
著作権者	CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン	publisher
査読	有り
PubMed ID	24145732
Web of Science KeyUT	000325836100006

谷本 光音